NASDAQ:GLTO
Galecto, Inc. Stock News
$0.630
+0.0052 (+0.83%)
At Close: May 24, 2024
Galecto to Present at the Upcoming Jefferies Healthcare Conference
08:00am, Tuesday, 30'th May 2023
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fi
Galecto to Present Two Posters at AACR Annual Meeting 2023
08:30am, Thursday, 13'th Apr 2023
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for
Orbimed Advisors Now Owns 10.5% of Galecto
10:21pm, Monday, 10'th Apr 2023
Fintel reports that Orbimed Advisors has filed a 13D/A form with the SEC disclosing ownership of 2.70MM shares of Galecto Inc (GLTO).
All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy
01:33pm, Friday, 11'th Nov 2022
Galecto, Inc. (GLTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for
Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022
06:00am, Monday, 17'th Oct 2022
BOSTON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced t
Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference
08:30am, Tuesday, 06'th Sep 2022
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced
Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting
08:30am, Thursday, 26'th May 2022
Novel galectin-3-based mechanism of PD-1/PD-L1 checkpoint inhibitor resistance identified
Galecto GAAP EPS of -$2.05 beats by $0.08
10:11pm, Thursday, 17'th Feb 2022 Seeking Alpha
Galecto press release (GLTO): FY GAAP EPS of -$2.05 beats by $0.08.Cash, cash equivalents, and investments as of December 31, 2021 were approximately $109.2 million.
Galecto Reports Financial Results for the Year Ended December 31, 2021
10:00pm, Thursday, 17'th Feb 2022 GlobeNewswire
Continued pipeline progress with three potentially first-in-class product candidates
Boom Or Bust: Where Does Galecto Inc. (NASDAQ: GLTO) Stock Go From Here?
05:00pm, Saturday, 18'th Dec 2021 Marketing Sentinel
During the last session, Galecto Inc. (NASDAQ:GLTO)s traded shares were 0.91 million. At the end of the trading day, the stocks price was $2.82, reflecting an intraday gain of 22.61% or $0.52. The 52-week high for the GLTO share is $16.41, that puts it down -481.91 from that peak though still a striking 21.28% gain Boom Or Bust: Where Does Galecto Inc. (NASDAQ: GLTO) Stock Go From Here? Read More »
Brokerages Anticipate Galecto, Inc. (NASDAQ:GLTO) to Announce -$0.56 Earnings Per Share
08:58pm, Sunday, 12'th Dec 2021 Dakota Financial News
Brokerages predict that Galecto, Inc. (NASDAQ:GLTO) will announce ($0.56) earnings per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Galectos earnings. The company is expected to issue its next earnings results on Monday, April 4th. According to Zacks, analysts expect that Galecto will report full year earnings of ($2.12) []
Zacks Investment Research Upgrades Galecto (NASDAQ:GLTO) to Buy
11:08am, Saturday, 11'th Dec 2021 Dakota Financial News
Zacks Investment Research upgraded shares of Galecto (NASDAQ:GLTO) from a hold rating to a buy rating in a report published on Friday, Zacks.com reports. Zacks Investment Research currently has $2.75 target price on the stock. According to Zacks, Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on []
-$0.56 EPS Expected for Galecto, Inc. (NASDAQ:GLTO) This Quarter
11:22am, Wednesday, 08'th Dec 2021 Dakota Financial News
Brokerages predict that Galecto, Inc. (NASDAQ:GLTO) will post earnings of ($0.56) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Galectos earnings. The business is scheduled to report its next quarterly earnings results on Monday, April 4th. On average, analysts expect that Galecto will report full year []
Galecto (NASDAQ:GLTO) Stock Rating Upgraded by Zacks Investment Research
09:26am, Sunday, 05'th Dec 2021 Dakota Financial News
Zacks Investment Research upgraded shares of Galecto (NASDAQ:GLTO) from a hold rating to a buy rating in a research report released on Wednesday morning, Zacks.com reports. They currently have $3.25 target price on the stock. According to Zacks, Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on []